| Ytd | 37.75% | |
| 1y | 99.91% |
| Open | 21.45 | Prev Close | 21.45 | Low | 21.40 | High | 22.54 | Mkt Cap | 3.58B |
| Vol | 3.28M | Avg Vol | 2.46M | EPS | -0.32 | P/E | N/A | Forward P/E | -88.47 |
| Beta | 2.15 | Short Ratio | 3.46 | Inst. Own | 96.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 15.76 | 200-d Avg | 15.75 | 1yr Est | 20.29 |
ADPT News
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and ra
U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares j
William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve fl
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and mainta
Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announ
Adaptive Biotechnologies plans to separate its businesses as clonoSEQ profitability and revenue grow
(Editor’s note: The lede, headline, futures and economic data were updated.) U.S. stock futures w
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open
Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Bust
Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company focused
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexib